CA2268840C - Benzimidazole-2-carbamates for the treatment of viral infections and cancer - Google Patents
Benzimidazole-2-carbamates for the treatment of viral infections and cancer Download PDFInfo
- Publication number
- CA2268840C CA2268840C CA002268840A CA2268840A CA2268840C CA 2268840 C CA2268840 C CA 2268840C CA 002268840 A CA002268840 A CA 002268840A CA 2268840 A CA2268840 A CA 2268840A CA 2268840 C CA2268840 C CA 2268840C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- agents
- composition according
- benzimidazole derivative
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals and can be used to treat viral infections that comprises a fungicide is disclosed. The particular fungicide used is a benzimidazole derivative having formula (I), wherein R is selected from the group consisting of H, carboxyl (-CO2H). hydroxyl, amino or esters (-CO2R') wherein R' is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or CH3CH2(OCH2CH2)n- or CH3CH2CH2(OCH2CH2CH2)n- or (CH3)2CH-(OCH(CH3)CH2)n- wherein n is from 1-3, the pharmaceutically acceptable salts thereof, or mixtures thereof.</SD OAB>
Description
BENZIMIDAZOLE-2-CARBAMAT'ES FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER
TECHNICAL FIELD
This invention is a pharmaceutical composition that is effective in the treatment of HIV and other viral infections and inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a benzimidazole derivative, the pharmaceutically acceptable salts thereof or mixtures thereof with other viral and cancer treatments.
BACKGROUND OF THE INVENTION
HIV and other viral infections are one leading cause of death. HIV is a disease in which a virus is replicated in the body which attacks the body's immune system. The HIV virus is not easily destroyed nor is there a good mechanism for keeping the host cells from replicating the virus. Herpes Simplex is another viral infection which is difficult, if not impossible, to cure. A method of treating these diseases and other viral infections is highly desirable. Clearly a material which would target the HIV virus and inhibit viral replication is highly desirable.
Cancers are a leading cause of death in animals and humans. The exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.
Many types of chemotherapeutic agents have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells.
The exact mechanism for the action of these chemotherapeutic agents are not always known.
Despite advances in the field of cancer treatment the leading therapies to date are surgery, radiation and chemotherapy. Chemotherapeutic approaches are said to fight cancers that are metastasized or ones that are particularly aggressive.
Such cytocidal or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing. To date, hormones, in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylafing agents, and anti-metabolites form the bulk of therapies available to oncologists. Ideally cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable.
Unfortunately, none have been found and instead agents which target especially rapidly dividing cells (both tumor and normal) have been used.
Clearly, the development of materials that would target tumor cells due to some unique specificity for them would be a breakthrough. Alternatively, materials that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable. Therefore, it is an object of this invention to provide a pharmaceutical composition that is effective in inhibiting the growth of tumors and cancers in mammals with mild or no effects on normal cells.
More specifically, it is an object of this invention to provide an anti-cancer composition comprising a pharmaceutical carrier and a benzimidazole derivative as defined herein along with a method for treating such cancers.
These compositions are also effective against viruses and can be used to treat viral infections. Therefore it is another object of this invention to provide a method of treating viral infections such as HIV, influenza and rhinoviruses.
These and other objects will become evident from the following detailed description of this inventions.
A pharmaceutical composition for treatment of viral infections and cancer in mammals, and in particular, warm blooded animals and humans, comprising a pharmaceutical carrier and an effective amount of compound having the formula:
H
R \
wherein R is selected from the group consisting of H, carboxyl (-COOH), hydroxyl, amino or esters (-C02R ) wherein R is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or CH3CH~(OCH~CH2)n or CH3CH2CH2(OCH~CH2CH2)ri or (CH~)~CH-and / I H
\ \ I , - O
and(OCH(CH3)CH~)n wherein n is from 1-3 or the pharmaceutically acceptable inorganic or organic acid salts thereof, or mixtures thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, 2-cyclopropylethyl, cyclopropylmethyl, 2-cyclopropyl propyl or ?-cyclopropylpropyl orcyclohexyimethyl. Preferred compounds are those having the formulas:
and H ~;
and and H \
' O .
These compositions can be used to inhibit the growth of cancers and other tumors in humans or animals by administration of an effective amount either orally, rectaIly, topically or parenterally, intravenously or by injection into the tumor.
DETAILED DESCRIPTION OF THE INVENTION
A. Definitions:
As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans andlor animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will; obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
As used herein, a "pharmaceutical addition salts" is salt of the anti-cancer compound with an organic or inorganic acid. These preferred acid. addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates. citrates, benzoates, salicylates, ascorbates, and the like.
As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.
As used herein, "cancer" refers to all types of cancers or neoplasm or malignant tumors found in mammals, including leukemia.
As used herein, the "anti-cancer compounds" are benzimidazole derivatives.
and their salts. The exact benzirnidazoles derivatives are described in detail below.
As used herein "chemotherapeutic agents" includes DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others, such as Asparaginase or hydroxyurea.
As used herein, "viruses" includes viruses which cause diseases (viral infection) in man and other warm blooded animals such as HIV virus. herpes, influenza and rhinoviruses.
As used herein "potentiators" are materials such as triprolidine and its cis-isomer and procodazole which are used in combination with the chemotherapeutic agents and herbicidal or fungicidal agents.
As used herein "significantly reduce" means to reduce the mass of the tumor by significant amount. This will usually be to less than ~0% of its ori~~inal mass, and preferably to reduce the mass to non-detectable amounts.
B. THE ANTI-CANCER AND ANTI-VIRAL COMPOUNDS
The anti-cancer compounds are benzimidazole derivatives. These derivatives have the formula:
R \ ~ H
wherein R is selected from the group consisting of H, carboxyl (-COSH), hydroxyl, amino or esters (-C02R~) wherein R is selected from the group consisting of alkoxy, haloalkyl, aikenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or CH3CH~(OCH2CH2)ri or CH3CH~CH2(OCH~CH~CH2)n or (CH3)~CH-(OCH(CH3)CH2)n wherein n is from 1-3 and the pharmacuetically acceptable organic or inorganic addition salts thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, cyclopropylethyl, cyclopropylmethyl, 2-cyclopropyl propyl or 2-cyclopropylpropyl or cyclohexylmethyl. Preferred compounds are those having the formulas:
H
C
and H
and H
\ \~ \
O
and / w~ H
and and H ~ \
O
C. HIV DRUGS
HIV is treated with two general classes of drugs, reverse transcriptase inhibitors and protease inhibitors. AZT is widely used to treat acute HIV. The herbicidal and fungicidal agents and their derivatives can be used in conjunction with AZT for the treatment of acute HIV. They do not interfere with the activity of the AZT.
Other HIV and antiviral agents can be used in conjunction with the therapy provided by this invention. These would include reverse transcriptase inhibitors and protease inhibitors. The drugs can be used concurrently or given in sequence with the herbicidal or fungicidal agents.
D. CHEMOTHERAPEUTIC AGENTS
The fungicides and herbicides can be administered with chemotherapeutic agents. This can be in sequence, where the chemotherapeutic agent is used to debulk the tumor and then the treatment with the herbicide or fungicide begins, or the two materials can be administered together.
The cheniotherapeutic agents are generally grouped as DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others such as Asparaginase or hydroxyurea. Each of the groups of chemotherapeutic agents can be further divided by type of activity or compound. The chemotherapeutic agents used in the sequential method in combination herbicidal or fungicidal agents s primarily include members of the DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents groups. For a detailed discussion of the chemotherapeutic agents and their method of administration, see Dorr, et al.
Cancer C'hemotherapv Handbook, 2d edition, pages 15-34, Appleton & Lange (Connecticut, 1994) herein incorporated by reference.
In order to reduce the mass of the tumor or stop the growth of the cancer cells, the chemotherapeutic agent must prevent the cells from replicating and also must interfere with the cell's ability to maintain itself. The agents which do this are primarily the DNA-interactive agents such as Cisplatin, and tubulin interactive agents.
DNA-Interactive Agents include the alkylating agents, e.g. Cisplatin, Cyclophosphamide, Altretamine; the DNA strand-breakage agents, such as Bleomycin; the intercalating topoisomerase II inhibitors, e.g., Dactinomycin and Doxorubicin); the nonintercalating topoisomerase II inhibitors such as, Etoposide and Teniposide; and the DNA minor groove binder Plcamydin.
The alkylating agents form covalent chemical adducts with cellular DNA, RNA, and protein molecules and with smaller amino acids, glutathione and similar chemicals. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and the role of these alkylating agents in cancer therapy is not well understood. Typical alkylating agents include:
Nitrogen mustards, such as Chlorambucil, Cyclophosphamide, Isofamide, Mechiorethamine, Melphalan, Uracil mustard;
aziridines such as Thiotepa;
methanesulfonate esters such as Busulfan;
nitroso ureas, such as Carmustine, Lomustine, Streptozocin;
platinum complexes, such as Cisplatin, Carboplatin;
bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine;
DNA strand breaking agents include Bleomycin;
DNA topoisomerase II inhibitors include the following:
Intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, and Mitoxantrone;
nonintercalators, such as Etoposide and Teniposide.
The DNA minor groove binder is Plicamycin.
The antimetabolites interfere with the production of nucleic acids by one or the other of two major mechanisms. Some of the drugs inhibit production of the deoxyribonucleoside triphosphates that are the immediate precursors for DNA
synthesis, thus inhibiting DNA replication. Some of the compounds are sufficiently like purines or pyrimidines to be able to substitute for them in the anabolic nucleotide pathways. These analogs can then be substituted into the DNA and RNA
instead of their normal counterparts. The antimetabolites useful herein include:
folate antagonists such as Methotrexate and trimetrexate pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine, and Floxuridine purine antagonists include Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin;
sugar modified analogs include Cyctrabine, Fludarabine;
ribonucleotide reductase inhibitors include hydroxyurea.
Tubulin Interactive agents act by binding to specific sites on tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical cell structure units. When the interactive agents bind on the protein, the cell can not form microtubules Tubulin Interactive agents include Vincristine and Vinblastine, both alkaloids and Paclitaxel.
Adrenal corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti inflammatory benefits as well as the ability of some to inhibit mitotic divisions and to halt DNA synthesis.
These compounds include, Prednisone, Dexamethasone, Methylprednisolone, and Prednisolone.
Hydroxyurea appears to act primarily through inhibition of the enzyme ribonucleotide reductase.
Asparagenase is an enzyme which converts asparagine to nonfunctional aspartic acid and thus blocks protein synthesis in the tumor.
The hormonal agents and leutinizing hormones are not usually used to substantially reduce the tumor mass. However, they can be used in conjunction with the chemotherapeutic agents or the herbicidal or fungicidal agents s.
Hormonal blocking agents are also useful in the treatment of cancers and tumors. They are used in hormonally susceptible tumors and are usually derived from natural sources. These include:
estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbesterol, Chlorotrianisene and Idenestrol;
progestins such as Hydroxyprogesterone caproate, Medroxvprogesterone, and Megestrol;
androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone;
Leutinizing hormone releasing hormone agents or gonadotropin-releasing hormone antagonists are used primarily the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate. They prevent the biosynthesis of steroids in the testes.
Antihormonal antigens include:
antiestrogenic agents such as Tamosifen, antiandrogen agents such as Flutamide ; and antiadrenal agents such as Mitotane and Aminoglutethirnide.
E. POTENTIATORS
The "potentiators" can be any material which improves or increases the efficacy of the pharmaceutical composition and/or act on the immune system.
One such potentiator is triprolidine and its cis-isomer which are used in combination with the chemotherapeutic agents and the fungicide or herbicide. Triprolidine is described in US 5,114,951 ( 1992). Another potentiator is procodazole, 1 H-Benzimidazole-2-propanoic acid; [f3-(2-benzimidazole) propionic acid; 2-(2-carboxyethyl)benzimidazole; propazol) Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections and can be used with the compositions claimed herein.
The potentiators can improve the efficacy of the herbicidal or fungicidal compounds and can be used in a safe and effective amount. These combinations can be administered to the patient or animal by oral, rectal, topical or parenteral administration.
Antioxidant vitamins such as ascorbic acid, beta-carotene, vitamin A and vitamin E can be administered with the compositions of this invention.
F. DOSAGE
Any suitable dosage may be given in the method of the invention. The type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor being treated. Generally a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight and to as much as about 4000 mg per kg of body weight is suitable.
Preferably from 15 mg to as much as about 1500 mg/kg of body weight is used.
For the chemotherapeutic agents, a cower dosage may be appropriate, i.e., from about 0.01 mg/kg of body weight to about 400 mg/kg body weight, although amounts up to 1 S00 mg/kg can be used. Any suitable dosage can be given in the method of the invention for treating HIV. The type of compounds and the carriers and the amount will vary widely depending on the species of the warm blooded animal or human, body weight. The range and ratio of the fungicidal or herbicidal agents and their derivatives and the HIV treating agent used will depend on the type of agent.
Generally, for the herbicidal or fungicidal agents and their derivatives a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight to as much as about 4000 mg per kg of body weight is suitable. Higher dosages, up to 6000 mglkg can also be used. Preferably from 15 mg to as high a level as about 3000 mg/kg of body weight is used for the herbicidal or fungicidal agents. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. For the HIV agents from about 0.01 mg/kg to as much as 1500 mg/kg can be used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. The dosage unit can also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration or injection into or around the tumor.
G. DOSAGE DELIVERY FORMS
The anti-cancer compounds are typically mixed with a pharmaceutically acceptable earner. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. The active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, .flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents. Oral dosage forms optionally contain flavorants and coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.
Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in US. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 3 0 (Banker &
Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets ( 1981 ); and Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition ( 1976).
H. METHOD OF TREATMENT
The method of treatment can be any suitable method which is effective in the treatment of the particular virus, cancer or tumor type that is being treated.
Treatment may be oral, rectal, topical, parenteral or intravenous administration or by injection into the tumor and the like. The method of applying or administering an effective amount also varies depending on the tumor or virus being treated. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the benzimiadzole derivatives forme~ated with an appropriate carrier.
Additional anti-viral materials can be used along mth the benzimidazoles derivatives as well as additional cancer inhibiting compounds) can be combined in the cancer treatments. Diluents can be used to facilitate application or administration is the preferred method of administering the compounds to warm blooded animals.
For the treatment of viral infections, the benzimidazole derivative is administered in doses for 7 to about 21 days or longer if needed to inhibit the growth or to kill the virus. In the case of chronic infections, these agents may need to be given for extended periods of time, up to years.
For the treatment of acute viral infections or HIV, the benzimidazole derivative can be administered after an AZT treatment or in conjunction with other HIV therapies. These drugs can be also administered in a sequential regimen in which the HIV virus is first reduced in the body and then the benzimidazole derivative is administered to keep the virus from continuing to replicate. AZT
therapy can be continued during the treatment with the benzimidazole derivatives treatment. If the disease is in the early stages, the benzimidazole derivatives can be administered to keep the virus from replicating~or growing and thus slow the progress of the disease.
I '?
In cancer treatments, preferably, the benzimidazole derivative is administered first to significantly reduce the size of the cancer or tumor mass. Usually this will take 3 to about 14 days. The reduction in the tumor or level of cancer cells will be to less than ~0% of the original level. Radiation therapy may be used in conjunction with benzimidazole derivatives agent treatment.
Once the tumor has been reduced, the benzimidazole derivative is administered. Because of the relative safety of this material, it can be administered for from 14 days to 365 days as needed to maintain its effectiveness in reducing the regrowth of the cancer.
The following examples are illustrative and are not meant to be limiting to the invention.
Example I
Each of the following compounds was tested for solubility, growth inhibition in a MTT assay against B 16 Murine Melanoma and I-IT29, reported as IC50(~M), tubulin polymerization inhibition and indirect binding with calf thymus DNA
using a Methyl Green displacement. The following results were achieved:
Compound Tested:
H I \
Estimated loge solubility I .46 ~0.60 Growth Inhibitory Cell Line IC50(p.M) Activity (MTT Assay) B 16 (Murine Melanoma 4.925 HT29 (Human Colon 3.297 Carcinoma) Compound tested:
H ( \
Estimated loge solubility 1.99 ~0.89 Growth Inhibitory Cell Line IC50(!~M) Activity (MTT Assay) B 16 (Murine Melanoma 0.0844 1-IT29 (Human Colon 0.266 Carcinoma) Compound tested:
/
H
Cl \
O
Estimated IogP solubility 2.93 ~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.112 HT29 (Human Colon 0.102 Carcinoma) Compound Tested:
H
\ \
O
Estimated loge solubility 2.72 ~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.0440 HT29 (Human Colon 0.00786 Carcinoma) Compound Tested:
\ ( H
,,,,. v Estimated loge solubility 5.54 ~0.87 Growth Inhibitory Cell Line ICSp(pM) Activity (MTT Assay) B I 6 (Marine Melanoma 0.0769 Compound Tested:
Compound Tested:
Estimated loge solubility 4.61~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.0046 Estimated loge solubility 2.69~0.85 Growth Inhibitory Cell Line IC50(~cM) Activity (MTT Assay) B 16 (Marine Melanoma 0.06? 1 Compound Tested:
TECHNICAL FIELD
This invention is a pharmaceutical composition that is effective in the treatment of HIV and other viral infections and inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition contains a benzimidazole derivative, the pharmaceutically acceptable salts thereof or mixtures thereof with other viral and cancer treatments.
BACKGROUND OF THE INVENTION
HIV and other viral infections are one leading cause of death. HIV is a disease in which a virus is replicated in the body which attacks the body's immune system. The HIV virus is not easily destroyed nor is there a good mechanism for keeping the host cells from replicating the virus. Herpes Simplex is another viral infection which is difficult, if not impossible, to cure. A method of treating these diseases and other viral infections is highly desirable. Clearly a material which would target the HIV virus and inhibit viral replication is highly desirable.
Cancers are a leading cause of death in animals and humans. The exact cause of cancer is not known, but links between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors has been shown by a number of researchers.
Many types of chemotherapeutic agents have been shown to be effective against cancers and tumor cells, but not all types of cancers and tumors respond to these agents. Unfortunately, many of these agents also destroy normal cells.
The exact mechanism for the action of these chemotherapeutic agents are not always known.
Despite advances in the field of cancer treatment the leading therapies to date are surgery, radiation and chemotherapy. Chemotherapeutic approaches are said to fight cancers that are metastasized or ones that are particularly aggressive.
Such cytocidal or cytostatic agents work best on cancers with large growth factors, i.e., ones whose cells are rapidly dividing. To date, hormones, in particular estrogen, progesterone and testosterone, and some antibiotics produced by a variety of microbes, alkylafing agents, and anti-metabolites form the bulk of therapies available to oncologists. Ideally cytotoxic agents that have specificity for cancer and tumor cells while not affecting normal cells would be extremely desirable.
Unfortunately, none have been found and instead agents which target especially rapidly dividing cells (both tumor and normal) have been used.
Clearly, the development of materials that would target tumor cells due to some unique specificity for them would be a breakthrough. Alternatively, materials that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable. Therefore, it is an object of this invention to provide a pharmaceutical composition that is effective in inhibiting the growth of tumors and cancers in mammals with mild or no effects on normal cells.
More specifically, it is an object of this invention to provide an anti-cancer composition comprising a pharmaceutical carrier and a benzimidazole derivative as defined herein along with a method for treating such cancers.
These compositions are also effective against viruses and can be used to treat viral infections. Therefore it is another object of this invention to provide a method of treating viral infections such as HIV, influenza and rhinoviruses.
These and other objects will become evident from the following detailed description of this inventions.
A pharmaceutical composition for treatment of viral infections and cancer in mammals, and in particular, warm blooded animals and humans, comprising a pharmaceutical carrier and an effective amount of compound having the formula:
H
R \
wherein R is selected from the group consisting of H, carboxyl (-COOH), hydroxyl, amino or esters (-C02R ) wherein R is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or CH3CH~(OCH~CH2)n or CH3CH2CH2(OCH~CH2CH2)ri or (CH~)~CH-and / I H
\ \ I , - O
and(OCH(CH3)CH~)n wherein n is from 1-3 or the pharmaceutically acceptable inorganic or organic acid salts thereof, or mixtures thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, 2-cyclopropylethyl, cyclopropylmethyl, 2-cyclopropyl propyl or ?-cyclopropylpropyl orcyclohexyimethyl. Preferred compounds are those having the formulas:
and H ~;
and and H \
' O .
These compositions can be used to inhibit the growth of cancers and other tumors in humans or animals by administration of an effective amount either orally, rectaIly, topically or parenterally, intravenously or by injection into the tumor.
DETAILED DESCRIPTION OF THE INVENTION
A. Definitions:
As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans andlor animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
As used herein, the term "safe and effective amount" refers to the quantity of a component which is sufficient to yield a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, or allergic response) commensurate with a reasonable benefit/risk ratio when used in the manner of this invention. The specific "safe and effective amount" will; obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives.
As used herein, a "pharmaceutical addition salts" is salt of the anti-cancer compound with an organic or inorganic acid. These preferred acid. addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates. citrates, benzoates, salicylates, ascorbates, and the like.
As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent or vehicle for delivering the anti-cancer agent to the animal or human. The carrier may be liquid or solid and is selected with the planned manner of administration in mind.
As used herein, "cancer" refers to all types of cancers or neoplasm or malignant tumors found in mammals, including leukemia.
As used herein, the "anti-cancer compounds" are benzimidazole derivatives.
and their salts. The exact benzirnidazoles derivatives are described in detail below.
As used herein "chemotherapeutic agents" includes DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others, such as Asparaginase or hydroxyurea.
As used herein, "viruses" includes viruses which cause diseases (viral infection) in man and other warm blooded animals such as HIV virus. herpes, influenza and rhinoviruses.
As used herein "potentiators" are materials such as triprolidine and its cis-isomer and procodazole which are used in combination with the chemotherapeutic agents and herbicidal or fungicidal agents.
As used herein "significantly reduce" means to reduce the mass of the tumor by significant amount. This will usually be to less than ~0% of its ori~~inal mass, and preferably to reduce the mass to non-detectable amounts.
B. THE ANTI-CANCER AND ANTI-VIRAL COMPOUNDS
The anti-cancer compounds are benzimidazole derivatives. These derivatives have the formula:
R \ ~ H
wherein R is selected from the group consisting of H, carboxyl (-COSH), hydroxyl, amino or esters (-C02R~) wherein R is selected from the group consisting of alkoxy, haloalkyl, aikenyl, and cycloalkyl wherein the alkyl groups have from 1 - 8 carbons or CH3CH~(OCH2CH2)ri or CH3CH~CH2(OCH~CH~CH2)n or (CH3)~CH-(OCH(CH3)CH2)n wherein n is from 1-3 and the pharmacuetically acceptable organic or inorganic addition salts thereof. The preferred alkyl groups are straight chain. Preferably the halogen is substituted on the terminal carbon, and the halogen is chlorine. The preferred cycloalkyl groups are those having 3-6 carbon atoms. The cycloalkyl groups also include those which are substituted on an alkyl chain, cyclopropylethyl, cyclopropylmethyl, 2-cyclopropyl propyl or 2-cyclopropylpropyl or cyclohexylmethyl. Preferred compounds are those having the formulas:
H
C
and H
and H
\ \~ \
O
and / w~ H
and and H ~ \
O
C. HIV DRUGS
HIV is treated with two general classes of drugs, reverse transcriptase inhibitors and protease inhibitors. AZT is widely used to treat acute HIV. The herbicidal and fungicidal agents and their derivatives can be used in conjunction with AZT for the treatment of acute HIV. They do not interfere with the activity of the AZT.
Other HIV and antiviral agents can be used in conjunction with the therapy provided by this invention. These would include reverse transcriptase inhibitors and protease inhibitors. The drugs can be used concurrently or given in sequence with the herbicidal or fungicidal agents.
D. CHEMOTHERAPEUTIC AGENTS
The fungicides and herbicides can be administered with chemotherapeutic agents. This can be in sequence, where the chemotherapeutic agent is used to debulk the tumor and then the treatment with the herbicide or fungicide begins, or the two materials can be administered together.
The cheniotherapeutic agents are generally grouped as DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents, Hormonal agents and others such as Asparaginase or hydroxyurea. Each of the groups of chemotherapeutic agents can be further divided by type of activity or compound. The chemotherapeutic agents used in the sequential method in combination herbicidal or fungicidal agents s primarily include members of the DNA-interactive Agents, Antimetabolites, Tubulin-Interactive Agents groups. For a detailed discussion of the chemotherapeutic agents and their method of administration, see Dorr, et al.
Cancer C'hemotherapv Handbook, 2d edition, pages 15-34, Appleton & Lange (Connecticut, 1994) herein incorporated by reference.
In order to reduce the mass of the tumor or stop the growth of the cancer cells, the chemotherapeutic agent must prevent the cells from replicating and also must interfere with the cell's ability to maintain itself. The agents which do this are primarily the DNA-interactive agents such as Cisplatin, and tubulin interactive agents.
DNA-Interactive Agents include the alkylating agents, e.g. Cisplatin, Cyclophosphamide, Altretamine; the DNA strand-breakage agents, such as Bleomycin; the intercalating topoisomerase II inhibitors, e.g., Dactinomycin and Doxorubicin); the nonintercalating topoisomerase II inhibitors such as, Etoposide and Teniposide; and the DNA minor groove binder Plcamydin.
The alkylating agents form covalent chemical adducts with cellular DNA, RNA, and protein molecules and with smaller amino acids, glutathione and similar chemicals. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and the role of these alkylating agents in cancer therapy is not well understood. Typical alkylating agents include:
Nitrogen mustards, such as Chlorambucil, Cyclophosphamide, Isofamide, Mechiorethamine, Melphalan, Uracil mustard;
aziridines such as Thiotepa;
methanesulfonate esters such as Busulfan;
nitroso ureas, such as Carmustine, Lomustine, Streptozocin;
platinum complexes, such as Cisplatin, Carboplatin;
bioreductive alkylator, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine;
DNA strand breaking agents include Bleomycin;
DNA topoisomerase II inhibitors include the following:
Intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin, and Mitoxantrone;
nonintercalators, such as Etoposide and Teniposide.
The DNA minor groove binder is Plicamycin.
The antimetabolites interfere with the production of nucleic acids by one or the other of two major mechanisms. Some of the drugs inhibit production of the deoxyribonucleoside triphosphates that are the immediate precursors for DNA
synthesis, thus inhibiting DNA replication. Some of the compounds are sufficiently like purines or pyrimidines to be able to substitute for them in the anabolic nucleotide pathways. These analogs can then be substituted into the DNA and RNA
instead of their normal counterparts. The antimetabolites useful herein include:
folate antagonists such as Methotrexate and trimetrexate pyrimidine antagonists, such as Fluorouracil, Fluorodeoxyuridine, CB3717, Azacytidine, Cytarabine, and Floxuridine purine antagonists include Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin;
sugar modified analogs include Cyctrabine, Fludarabine;
ribonucleotide reductase inhibitors include hydroxyurea.
Tubulin Interactive agents act by binding to specific sites on tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical cell structure units. When the interactive agents bind on the protein, the cell can not form microtubules Tubulin Interactive agents include Vincristine and Vinblastine, both alkaloids and Paclitaxel.
Adrenal corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti inflammatory benefits as well as the ability of some to inhibit mitotic divisions and to halt DNA synthesis.
These compounds include, Prednisone, Dexamethasone, Methylprednisolone, and Prednisolone.
Hydroxyurea appears to act primarily through inhibition of the enzyme ribonucleotide reductase.
Asparagenase is an enzyme which converts asparagine to nonfunctional aspartic acid and thus blocks protein synthesis in the tumor.
The hormonal agents and leutinizing hormones are not usually used to substantially reduce the tumor mass. However, they can be used in conjunction with the chemotherapeutic agents or the herbicidal or fungicidal agents s.
Hormonal blocking agents are also useful in the treatment of cancers and tumors. They are used in hormonally susceptible tumors and are usually derived from natural sources. These include:
estrogens, conjugated estrogens and Ethinyl Estradiol and Diethylstilbesterol, Chlorotrianisene and Idenestrol;
progestins such as Hydroxyprogesterone caproate, Medroxvprogesterone, and Megestrol;
androgens such as testosterone, testosterone propionate; fluoxymesterone, methyltestosterone;
Leutinizing hormone releasing hormone agents or gonadotropin-releasing hormone antagonists are used primarily the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate. They prevent the biosynthesis of steroids in the testes.
Antihormonal antigens include:
antiestrogenic agents such as Tamosifen, antiandrogen agents such as Flutamide ; and antiadrenal agents such as Mitotane and Aminoglutethirnide.
E. POTENTIATORS
The "potentiators" can be any material which improves or increases the efficacy of the pharmaceutical composition and/or act on the immune system.
One such potentiator is triprolidine and its cis-isomer which are used in combination with the chemotherapeutic agents and the fungicide or herbicide. Triprolidine is described in US 5,114,951 ( 1992). Another potentiator is procodazole, 1 H-Benzimidazole-2-propanoic acid; [f3-(2-benzimidazole) propionic acid; 2-(2-carboxyethyl)benzimidazole; propazol) Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections and can be used with the compositions claimed herein.
The potentiators can improve the efficacy of the herbicidal or fungicidal compounds and can be used in a safe and effective amount. These combinations can be administered to the patient or animal by oral, rectal, topical or parenteral administration.
Antioxidant vitamins such as ascorbic acid, beta-carotene, vitamin A and vitamin E can be administered with the compositions of this invention.
F. DOSAGE
Any suitable dosage may be given in the method of the invention. The type of compound and the carrier and the amount will vary widely depending on the species of the warm blooded animal or human, body weight, and tumor being treated. Generally a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight and to as much as about 4000 mg per kg of body weight is suitable.
Preferably from 15 mg to as much as about 1500 mg/kg of body weight is used.
For the chemotherapeutic agents, a cower dosage may be appropriate, i.e., from about 0.01 mg/kg of body weight to about 400 mg/kg body weight, although amounts up to 1 S00 mg/kg can be used. Any suitable dosage can be given in the method of the invention for treating HIV. The type of compounds and the carriers and the amount will vary widely depending on the species of the warm blooded animal or human, body weight. The range and ratio of the fungicidal or herbicidal agents and their derivatives and the HIV treating agent used will depend on the type of agent.
Generally, for the herbicidal or fungicidal agents and their derivatives a dosage of as little as about 2 milligrams (mg) per kilogram (kg) of body weight to as much as about 4000 mg per kg of body weight is suitable. Higher dosages, up to 6000 mglkg can also be used. Preferably from 15 mg to as high a level as about 3000 mg/kg of body weight is used for the herbicidal or fungicidal agents. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. For the HIV agents from about 0.01 mg/kg to as much as 1500 mg/kg can be used. Generally, the dosage in man is lower than for small warm blooded mammals such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other cancer inhibiting compounds. The dosage unit can also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form such as pills, tablets, capsules and the like or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration or injection into or around the tumor.
G. DOSAGE DELIVERY FORMS
The anti-cancer compounds are typically mixed with a pharmaceutically acceptable earner. This carrier can be a solid or liquid and the type is generally chosen based on the type of administration being used. The active agent can be coadministered in the form of a tablet or capsule, as an agglomerated powder or in a liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsule or tablets can be easily formulated and can be made easy to swallow or chew; other solid forms include granules, and bulk powders. Tablets may contain suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, .flow-inducing agents, and melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents. Oral dosage forms optionally contain flavorants and coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system chosen.
Specific examples of pharmaceutical acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described in US. Pat. No. 3,903,297 to Robert, issued Sept. 2, 1975. Techniques and compositions for making dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 3 0 (Banker &
Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets ( 1981 ); and Ansel, Introduction to Pharmaceutical Dosage Forms 2nd Edition ( 1976).
H. METHOD OF TREATMENT
The method of treatment can be any suitable method which is effective in the treatment of the particular virus, cancer or tumor type that is being treated.
Treatment may be oral, rectal, topical, parenteral or intravenous administration or by injection into the tumor and the like. The method of applying or administering an effective amount also varies depending on the tumor or virus being treated. It is believed that parenteral treatment by intravenous, subcutaneous, or intramuscular application of the benzimiadzole derivatives forme~ated with an appropriate carrier.
Additional anti-viral materials can be used along mth the benzimidazoles derivatives as well as additional cancer inhibiting compounds) can be combined in the cancer treatments. Diluents can be used to facilitate application or administration is the preferred method of administering the compounds to warm blooded animals.
For the treatment of viral infections, the benzimidazole derivative is administered in doses for 7 to about 21 days or longer if needed to inhibit the growth or to kill the virus. In the case of chronic infections, these agents may need to be given for extended periods of time, up to years.
For the treatment of acute viral infections or HIV, the benzimidazole derivative can be administered after an AZT treatment or in conjunction with other HIV therapies. These drugs can be also administered in a sequential regimen in which the HIV virus is first reduced in the body and then the benzimidazole derivative is administered to keep the virus from continuing to replicate. AZT
therapy can be continued during the treatment with the benzimidazole derivatives treatment. If the disease is in the early stages, the benzimidazole derivatives can be administered to keep the virus from replicating~or growing and thus slow the progress of the disease.
I '?
In cancer treatments, preferably, the benzimidazole derivative is administered first to significantly reduce the size of the cancer or tumor mass. Usually this will take 3 to about 14 days. The reduction in the tumor or level of cancer cells will be to less than ~0% of the original level. Radiation therapy may be used in conjunction with benzimidazole derivatives agent treatment.
Once the tumor has been reduced, the benzimidazole derivative is administered. Because of the relative safety of this material, it can be administered for from 14 days to 365 days as needed to maintain its effectiveness in reducing the regrowth of the cancer.
The following examples are illustrative and are not meant to be limiting to the invention.
Example I
Each of the following compounds was tested for solubility, growth inhibition in a MTT assay against B 16 Murine Melanoma and I-IT29, reported as IC50(~M), tubulin polymerization inhibition and indirect binding with calf thymus DNA
using a Methyl Green displacement. The following results were achieved:
Compound Tested:
H I \
Estimated loge solubility I .46 ~0.60 Growth Inhibitory Cell Line IC50(p.M) Activity (MTT Assay) B 16 (Murine Melanoma 4.925 HT29 (Human Colon 3.297 Carcinoma) Compound tested:
H ( \
Estimated loge solubility 1.99 ~0.89 Growth Inhibitory Cell Line IC50(!~M) Activity (MTT Assay) B 16 (Murine Melanoma 0.0844 1-IT29 (Human Colon 0.266 Carcinoma) Compound tested:
/
H
Cl \
O
Estimated IogP solubility 2.93 ~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.112 HT29 (Human Colon 0.102 Carcinoma) Compound Tested:
H
\ \
O
Estimated loge solubility 2.72 ~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.0440 HT29 (Human Colon 0.00786 Carcinoma) Compound Tested:
\ ( H
,,,,. v Estimated loge solubility 5.54 ~0.87 Growth Inhibitory Cell Line ICSp(pM) Activity (MTT Assay) B I 6 (Marine Melanoma 0.0769 Compound Tested:
Compound Tested:
Estimated loge solubility 4.61~0.86 Growth Inhibitory Cell Line IC50(~M) Activity (MTT Assay) B 16 (Marine Melanoma 0.0046 Estimated loge solubility 2.69~0.85 Growth Inhibitory Cell Line IC50(~cM) Activity (MTT Assay) B 16 (Marine Melanoma 0.06? 1 Compound Tested:
Claims (10)
1. A pharmaceutical composition for treating a carcinoma comprising a safe and effective amount of a benzimidazole derivative having the formula:
wherein, R is selected from the group consisting of hydroxyl, amino and -CO2R', and R' is selected from the group consisting of C8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-8, 11 alkenyl, C1-8 cycloalkyl, CH3CH2(OCH2CH2)n-, CH3CH2CH2(OCH2CH2CH2)n-, and (CH3)2CH-(OCH(CH3)CH2)n-, wherein n is from 1 to 3; and a pharmaceutically acceptable salt thereof, or a mixture thereof, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
wherein, R is selected from the group consisting of hydroxyl, amino and -CO2R', and R' is selected from the group consisting of C8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-8, 11 alkenyl, C1-8 cycloalkyl, CH3CH2(OCH2CH2)n-, CH3CH2CH2(OCH2CH2CH2)n-, and (CH3)2CH-(OCH(CH3)CH2)n-, wherein n is from 1 to 3; and a pharmaceutically acceptable salt thereof, or a mixture thereof, the pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
2. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative has the formula:
3. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative is:
4. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative is:
5. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative is:
6. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative is:
7. A pharmaceutical composition according to Claim 1 wherein said benzimidazole derivative is:
8. A pharmaceutical composition according to any one of claims 1-7 wherein said pharmaceutically acceptable salt is selected from the group consisting of chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, malates, citrates, benzoates, salicylates, ascorbates, and mixtures thereof.
9. Use of a pharmaceutical composition according to any one of claims 1-8 for reducing or inhibiting the growth of a carcinoma in warm blooded mammals.
10. A pharmaceutical composition in dosage unit form suitable for oral, rectal, topical, parenteral, or intravenous administration or by injection into a carcinoma for reducing or inhibiting metastasis and/or neoplastic growth in a warm blooded mammal, which comprises an active ingredient in accordance with any one of claims 1-8 in an amount effective to reduce or inhibit metastasis and/or neoplastic growth in a warm blooded mammal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/857,811 US6506783B1 (en) | 1997-05-16 | 1997-05-16 | Cancer treatments and pharmaceutical compositions therefor |
US08/857,811 | 1997-05-16 | ||
PCT/US1997/021565 WO1998051304A1 (en) | 1997-05-16 | 1997-11-26 | Benzimidazole-2-carbamates for the treatment of viral infections and cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2268840A1 CA2268840A1 (en) | 1998-11-19 |
CA2268840C true CA2268840C (en) | 2006-10-03 |
Family
ID=25326784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002268840A Expired - Fee Related CA2268840C (en) | 1997-05-16 | 1997-11-26 | Benzimidazole-2-carbamates for the treatment of viral infections and cancer |
Country Status (22)
Country | Link |
---|---|
US (13) | US6506783B1 (en) |
EP (1) | EP0956017B1 (en) |
JP (1) | JP2001527523A (en) |
KR (1) | KR20000049065A (en) |
CN (1) | CN1254282A (en) |
AR (1) | AR010008A1 (en) |
AT (1) | ATE363904T1 (en) |
AU (1) | AU728690B2 (en) |
BR (1) | BR9714634A (en) |
CA (1) | CA2268840C (en) |
CZ (1) | CZ125299A3 (en) |
DE (1) | DE69737793D1 (en) |
HU (1) | HUP0001170A3 (en) |
IL (1) | IL129352A0 (en) |
NO (1) | NO991700L (en) |
NZ (1) | NZ335159A (en) |
PE (1) | PE11099A1 (en) |
PL (1) | PL335541A1 (en) |
SK (1) | SK47099A3 (en) |
TR (1) | TR199901528T2 (en) |
WO (1) | WO1998051304A1 (en) |
ZA (1) | ZA979096B (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
US6423734B1 (en) * | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
US6608096B1 (en) * | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6462062B1 (en) * | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
WO2002041891A2 (en) * | 2000-11-01 | 2002-05-30 | The Procter & Gamble Company | Hiv treatment with benzimidazoles |
DE60117858T2 (en) * | 2000-12-07 | 2006-11-30 | Universiteit Utrecht Holding B.V. | COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES |
CA2434654A1 (en) | 2001-01-11 | 2002-09-06 | Board Of Regents, The University Of Texas System | Antihelminthic drugs as a treatment for hyperproliferative diseases |
US6515074B2 (en) * | 2001-01-22 | 2003-02-04 | Delphi Technologies, Inc. | Thermoplastic polymer alloy compositions and process for manufacture thereof |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
AUPR626001A0 (en) * | 2001-07-10 | 2001-08-02 | Mcgregor, Neil | A method of treatment and/or prophylaxis |
AU2002330088B2 (en) * | 2001-09-24 | 2009-09-03 | Jessie L.-S. Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
CA2478470A1 (en) * | 2002-03-26 | 2003-10-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Solubilization of weak bases |
US20050152962A1 (en) * | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
US8492443B2 (en) * | 2002-07-08 | 2013-07-23 | Joe S. Wilkins, Jr. | Treatment for herpes simplex virus and other infectious diseases |
EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
AU2003900064A0 (en) * | 2003-01-09 | 2003-01-23 | Penam Investments Pty. Ltd. | A method of treatment or prophylaxis of viral infection. |
KR20050122210A (en) * | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | Histone deacetylase inhibitors |
EP1598353A1 (en) * | 2004-05-17 | 2005-11-23 | Boehringer Ingelheim International GmbH | Pyrrolobenzimidazolones and their use as antiproliferative agents |
JP2008515956A (en) * | 2004-10-12 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 11.beta.-hydroxysteroid dehydrogenase type 1 active spiro compound |
US7193254B2 (en) * | 2004-11-30 | 2007-03-20 | International Business Machines Corporation | Structure and method of applying stresses to PFET and NFET transistor channels for improved performance |
EP1830847B1 (en) * | 2004-12-06 | 2014-11-19 | Pitney Pharmaceuticals Pty Limited | Treatment for cancer |
EP2329841A1 (en) | 2005-02-04 | 2011-06-08 | Survac ApS | Survivin peptide vaccine |
US7265248B1 (en) | 2005-04-29 | 2007-09-04 | Technology Innovations, Llc | Compositions and methods for the treatment of malaria |
KR20080069189A (en) * | 2005-11-01 | 2008-07-25 | 트랜스테크 파르마, 인크. | Pharmaceutical use of substituted amides |
WO2007051810A2 (en) * | 2005-11-01 | 2007-05-10 | Transtech Pharma | Pharmaceutical use of substituted amides |
AU2006312407A1 (en) * | 2005-11-09 | 2007-05-18 | Philera New Zealand Limited | Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits |
EP1991226B1 (en) * | 2006-02-28 | 2013-03-20 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase |
JP2009530346A (en) * | 2006-03-21 | 2009-08-27 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | Adamantane derivatives for the treatment of metabolic syndrome |
JP2009532418A (en) | 2006-04-07 | 2009-09-10 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | 11β-Hydroxysteroid dehydrogenase type 1 active compound |
US20100003679A1 (en) * | 2006-06-09 | 2010-01-07 | University Of Miami | Assessment of cellular composition and fractional viability and uses thereof |
WO2007144394A2 (en) * | 2006-06-16 | 2007-12-21 | High Point Pharmaceuticals, Llc. | Pharmaceutical use of substituted piperidine carboxamides |
EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
CA2657078A1 (en) * | 2006-07-13 | 2008-01-17 | High Point Pharmaceuticals, Llc | 11beta-hydroxysteroid dehydrogenase type 1 active compounds |
JP2010519240A (en) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー | N-adamantylbenzamide as an inhibitor of 11-beta-hydroxysteroid dehydrogenase |
US8334305B2 (en) * | 2007-02-23 | 2012-12-18 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase |
CN101679217A (en) * | 2007-02-23 | 2010-03-24 | 高点制药有限责任公司 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
US20110003852A1 (en) * | 2007-02-23 | 2011-01-06 | Soren Ebdrup | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
BRPI0721430A2 (en) * | 2007-03-09 | 2013-01-08 | High Point Pharmaceuticals Llc | indole amides and benzimidazole as hydroxysteroid dehydrogenase inhibitors |
EP2141990A4 (en) * | 2007-03-28 | 2011-07-06 | High Point Pharmaceuticals Llc | 11beta-hsd1 active compounds |
ES2399912T3 (en) * | 2007-04-11 | 2013-04-04 | High Point Pharmaceuticals, Llc | New compounds |
CA2685036A1 (en) * | 2007-04-24 | 2008-11-06 | High Point Pharmaceuticals, Llc | Pharmaceutical use of substituted amides |
EP3103791B1 (en) | 2007-06-27 | 2018-01-31 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CN101808518A (en) * | 2007-06-27 | 2010-08-18 | 默沙东公司 | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
US8771693B2 (en) | 2009-10-27 | 2014-07-08 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2012015715A1 (en) | 2010-07-27 | 2012-02-02 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators |
US10487114B2 (en) | 2011-04-27 | 2019-11-26 | Beth Israel Deaconess Medical Center, Inc. | Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof |
NZ721900A (en) | 2012-05-09 | 2018-01-26 | Univ Western Health Sciences | Proliposomal testosterone formulations |
WO2014082085A1 (en) * | 2012-11-26 | 2014-05-30 | The University Of North Carolina At Chapel Hill | Use of itk inhibitors for the treatment of cancer |
WO2016077648A1 (en) * | 2014-11-11 | 2016-05-19 | Neymeyer Calvin E | Method of treating pre-cancerous lesion with glyphosate, and compositions thereof |
WO2016187767A1 (en) * | 2015-05-25 | 2016-12-01 | Hutchison Medipharma Limited | Pharmaceutical compositions and use thereof |
US11547696B2 (en) | 2016-10-28 | 2023-01-10 | Children's Hospital Medical Center | Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias |
CN109633026A (en) * | 2019-01-03 | 2019-04-16 | 上海市农业科学院 | A kind of method that liquid chromatography-tandem mass spectrometry detects carbendazim and its metabolin |
KR102583547B1 (en) | 2020-03-30 | 2023-10-06 | (주)바이오메트릭스 테크놀로지 | Novel benzimidazole derivatives, preparation thereof and use thereof as anti-cancer agent comprising the same |
EP3907230A1 (en) | 2020-03-30 | 2021-11-10 | Biometrix Technology Inc. | Novel benzimidazole derivatives, preparation method thereof and use thereof as anti-cancer agent comprising the same |
KR102449266B1 (en) | 2020-06-23 | 2022-09-30 | (주)바이오메트릭스 테크놀로지 | Novel benzimidazole-carbohydrate conjugate compounds with anti-cancer activity and antiviral activity and their manufacturing method |
KR102342313B1 (en) | 2021-08-27 | 2021-12-24 | (주)바이오메트릭스 테크놀로지 | Micelle comprising benzimidazole-carbohydrate conjugate compound, preparation thereof and use thereof as anti-cancer agent or anti-virus agent comprising the same |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE158398C (en) | ||||
DE136499C (en) | ||||
US2933502A (en) * | 1958-02-12 | 1960-04-19 | Du Pont | Benzimidazolone derivatives |
US3010968A (en) | 1959-11-25 | 1961-11-28 | Du Pont | Process for manufacture of certain alkyl esters of benzimidazole carbamic acids |
NL134354C (en) | 1963-05-23 | |||
US3499761A (en) | 1964-07-20 | 1970-03-10 | Gaf Corp | Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents |
BE666795A (en) | 1964-08-04 | 1966-01-13 | ||
USRE28403E (en) | 1964-08-04 | 1975-04-29 | Butyl and n-propoxy-z-carbo- methoxyaminobenzimidazoles | |
US3541213A (en) | 1966-05-06 | 1970-11-17 | Du Pont | Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles |
US3399212A (en) * | 1966-05-16 | 1968-08-27 | Smith Kline French Lab | Benzimidazole ureas |
US3480642A (en) * | 1967-03-22 | 1969-11-25 | Smithkline Corp | Process for producing 2-carbalkoxyaminobenzimidazoles |
US3881014A (en) | 1968-11-05 | 1975-04-29 | Bayer Ag | N-tritylimidazoles for treating fungal infections |
BE744970A (en) | 1969-01-28 | 1970-07-27 | Lilly Co Eli | ANTIVIRAL AND IMMUNODEPRESSANT AGENTS |
BE759337A (en) | 1969-11-24 | 1971-05-24 | Lilly Co Eli | BENZIMIDAZOL (2,1-B) -QUINAZOLIN (6H) ONES WHICH ARE IMMUNO DEPRESSANTS, AND NEW BENZIMIDAZO (2,1-B) QUINAZOLIN-12- (6H) ONES |
FR2046114A5 (en) | 1970-01-30 | 1971-03-05 | Dynachim Sarl | Benzimidazole derivs anthelmintic, antifung - al bactericidal, aericidal, insecticidal, nema |
US3956262A (en) | 1970-12-09 | 1976-05-11 | Beecham Group Limited | Triazenoimidazoles |
US3738995A (en) | 1971-05-14 | 1973-06-12 | Du Pont | Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates |
DE2144505A1 (en) | 1971-09-06 | 1973-03-15 | Boehringer Sohn Ingelheim | S-triazino-(1,2-a)-benzimidazoles - prepd from substd benzimidazole-carbamic acid esters and isocyanates, biocides esp agai |
FR2155888A1 (en) | 1971-10-13 | 1973-05-25 | Agot Aime | Solid anthelmintic composn - for more economical treatment of ruminants |
DE2227919C2 (en) * | 1972-06-08 | 1982-12-23 | Bayer Ag, 5090 Leverkusen | Process for the preparation of benzimidazol-2-yl-carbamic acid methyl ester |
DE2253324A1 (en) | 1972-10-31 | 1974-05-09 | Bayer Ag | 1-ALKOXYCARBONYL-2-SQUARE BRACKETS ON UP- (ALKOXYCARBONYL) -AMINO SQUARE BRACKETS FOR -BENZIMIDAZOLE, THE PROCESS FOR THEIR PRODUCTION AND THEIR USE AS FUNGICIDES |
US4046906A (en) | 1973-04-21 | 1977-09-06 | Hoechst Aktiengesellschaft | Salts of alkyl 2-benzimidazole-carbamate |
JPS5142565A (en) | 1974-10-09 | 1976-04-10 | Copal Co Ltd | onnoff taimaa |
US4001423A (en) * | 1975-06-20 | 1977-01-04 | Dodds Dale I | 2-(2-ethoxy)ethoxyethyl benzimidazolecarbamate |
DE2527677A1 (en) * | 1975-06-21 | 1977-01-20 | Bayer Ag | PROCESS FOR THE PREPARATION OF 2,4-DIOXO-1,2,3,4-TETRAHYDRO-S-TRIAZINO- SQUARE BRACKET TO 1,2-A SQUARE BRACKET TO -BENZIMIDAZOLE |
US4086235A (en) | 1976-04-12 | 1978-04-25 | Syntex (U.S.A.) Inc. | 5 (6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity |
IN159210B (en) | 1982-01-11 | 1987-04-11 | Council Scient Ind Res | |
IN158878B (en) | 1982-07-15 | 1987-02-07 | Council Scient Ind Res | |
HU193951B (en) | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
US4731366A (en) | 1986-08-05 | 1988-03-15 | Harbor Branch Oceanographic Institution, Inc. | Discorhabdin compositions and their methods of use |
GB2210875B (en) | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
US5149527A (en) | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
US5284662A (en) | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
JPH04223274A (en) | 1990-12-26 | 1992-08-13 | Kansei Corp | Acceleration sensor |
GB9106278D0 (en) | 1991-03-25 | 1991-05-08 | Smithkline Beecham Plc | Method of treatment |
US5364875A (en) | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
US5290801A (en) | 1992-05-29 | 1994-03-01 | The Du Pont Merck Pharmaceutical Company | Benzimidazoles for the treatment of atherosclerosis |
KR950702994A (en) | 1992-08-12 | 1995-08-23 | 로렌스 티. 웰츠 | PROTEIN KINASE INHIBITORS AND RELATED COMPOUNDS COMBINED WITH TAXOL |
FR2703057B1 (en) | 1993-03-24 | 1995-06-16 | Elysees Balzac Financiere | Cellulose cellular material containing a biocidal agent and process for its preparation. |
HUT74006A (en) | 1993-03-31 | 1996-10-28 | Merck & Co Inc | Hiv protease inhibitors in pharmaceutical combinations and pharmaceutical compns. contg. them |
US5434163A (en) | 1993-05-14 | 1995-07-18 | The Medical College Of Pennsylvania | Treatment of Cryptococcus neoformans infection |
US5554373A (en) | 1993-11-05 | 1996-09-10 | Seabrook; Samuel G. | Compositions containing anti-microbial agents and methods for making and using same |
JP3213471B2 (en) | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | Method for producing liposome preparation containing medicinal ingredient |
ZA962879B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
PL322732A1 (en) | 1995-04-12 | 1998-02-16 | Procter & Gamble | Pharmaceutic agent containing n-chlorophenyl carbaminates and n-chlorophenyl thiocarbaminates for inhibiting development of viruses and carcinoma |
US6479526B1 (en) * | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
NZ305784A (en) | 1995-04-12 | 2001-03-30 | Procter & Gamble | Benzimidazole containing medicaments for treating cancers, tumors and viral infections |
US5665713A (en) | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US5656615A (en) | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
US6262093B1 (en) * | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US5629341A (en) | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
ZA962880B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
MX9707809A (en) * | 1995-06-07 | 1998-01-31 | Procter & Gamble | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers. |
SK168697A3 (en) | 1995-06-07 | 1998-12-02 | Procter & Gamble | A medicament for the treatment of leukemia |
US5665751A (en) | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US20010039291A1 (en) * | 1995-06-07 | 2001-11-08 | The Procter & Gamble Company | Compositions and methods of treatment for cancer or viral infections |
US6265427B1 (en) * | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US6200992B1 (en) * | 1995-06-07 | 2001-03-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
BR9609920A (en) | 1995-08-03 | 1999-07-06 | Procter & Gamble | Use of griseofulvin to inhibit cancer growth |
MX9707808A (en) * | 1995-08-04 | 1998-01-31 | Procter & Gamble | A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers. |
CN1195288A (en) | 1995-08-04 | 1998-10-07 | 普罗克特和甘保尔公司 | Use of fluconazole for inhibiting growth of cancers |
US6686391B2 (en) * | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
US5908855A (en) | 1996-07-16 | 1999-06-01 | The Procter & Gamble Company | Compositions for treating viral infections |
AU6966696A (en) * | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
US5627094A (en) * | 1995-12-04 | 1997-05-06 | Chartered Semiconductor Manufacturing Pte, Ltd. | Stacked container capacitor using chemical mechanical polishing |
US6541213B1 (en) * | 1996-03-29 | 2003-04-01 | University Of Washington | Microscale diffusion immunoassay |
DE19623226A1 (en) * | 1996-06-11 | 1997-12-18 | Basf Ag | Catalyst systems of the Ziegler-Natta type |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US5825811A (en) | 1997-01-16 | 1998-10-20 | Motorola, Inc. | Method and apparatus for facilitating inbound channel access |
US5900429A (en) * | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
PE11499A1 (en) | 1997-05-16 | 1999-03-01 | Procter & Gamble | TREATMENT OF HIV AND CANCER |
US5908885A (en) * | 1997-07-01 | 1999-06-01 | University Of South Alabama | Polysuccinimide and polyaspartate as additives to cementitious materials |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
US6248843B1 (en) * | 1998-09-18 | 2001-06-19 | Mcwhorter Technologies, Inc. | Powder coatings based on branched oligoesters and triazole blocked polyisocyanates |
AU777977B2 (en) | 1998-10-09 | 2004-11-04 | General Mills Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
US6211177B1 (en) * | 1998-11-24 | 2001-04-03 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives |
US20010053773A1 (en) * | 1998-12-22 | 2001-12-20 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
AU2697100A (en) * | 1999-02-23 | 2000-09-14 | Yuhan Corporation | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6136835A (en) * | 1999-05-17 | 2000-10-24 | The Procter & Gamble Company | Methods of treatment for viral infections |
US6423734B1 (en) * | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6135835A (en) * | 1999-08-16 | 2000-10-24 | Future Beach Corporation | Aquatic vehicle |
US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
US6290929B1 (en) * | 2000-07-28 | 2001-09-18 | The Procter & Gamble Company | Cancer treatment |
US6518269B1 (en) * | 2000-07-28 | 2003-02-11 | University Of Arizona Foundation | Cancer treatment |
US6380232B1 (en) * | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
US6608096B1 (en) * | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6462062B1 (en) * | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
WO2002041891A2 (en) * | 2000-11-01 | 2002-05-30 | The Procter & Gamble Company | Hiv treatment with benzimidazoles |
-
1997
- 1997-05-16 US US08/857,811 patent/US6506783B1/en not_active Expired - Fee Related
- 1997-10-10 PE PE1997000897A patent/PE11099A1/en not_active Application Discontinuation
- 1997-10-10 ZA ZA979096A patent/ZA979096B/en unknown
- 1997-10-17 AR ARP970104815A patent/AR010008A1/en unknown
- 1997-11-26 SK SK470-99A patent/SK47099A3/en unknown
- 1997-11-26 HU HU0001170A patent/HUP0001170A3/en unknown
- 1997-11-26 CN CN97182190A patent/CN1254282A/en active Pending
- 1997-11-26 PL PL97335541A patent/PL335541A1/en unknown
- 1997-11-26 WO PCT/US1997/021565 patent/WO1998051304A1/en active IP Right Grant
- 1997-11-26 DE DE69737793T patent/DE69737793D1/en not_active Expired - Lifetime
- 1997-11-26 CA CA002268840A patent/CA2268840C/en not_active Expired - Fee Related
- 1997-11-26 JP JP52193098A patent/JP2001527523A/en not_active Ceased
- 1997-11-26 AU AU74027/98A patent/AU728690B2/en not_active Ceased
- 1997-11-26 AT AT97949600T patent/ATE363904T1/en not_active IP Right Cessation
- 1997-11-26 BR BR9714634-0A patent/BR9714634A/en unknown
- 1997-11-26 TR TR1999/01528T patent/TR199901528T2/en unknown
- 1997-11-26 IL IL12935297A patent/IL129352A0/en unknown
- 1997-11-26 NZ NZ335159A patent/NZ335159A/en unknown
- 1997-11-26 KR KR1019990703138A patent/KR20000049065A/en not_active Application Discontinuation
- 1997-11-26 EP EP97949600A patent/EP0956017B1/en not_active Expired - Lifetime
- 1997-11-26 CZ CZ991252A patent/CZ125299A3/en unknown
-
1999
- 1999-03-01 US US09/259,969 patent/US6077862A/en not_active Expired - Fee Related
- 1999-04-09 NO NO991700A patent/NO991700L/en not_active Application Discontinuation
-
2000
- 2000-09-29 US US09/676,031 patent/US6710065B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,407 patent/US6482843B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,029 patent/US6423735B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,202 patent/US6420411B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,032 patent/US6900235B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,409 patent/US6423736B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,030 patent/US6407131B1/en not_active Expired - Fee Related
- 2000-09-29 US US09/676,034 patent/US6864275B1/en not_active Expired - Fee Related
-
2003
- 2003-01-13 US US10/340,945 patent/US6984654B2/en not_active Expired - Fee Related
-
2004
- 2004-10-21 US US10/970,346 patent/US20050192328A1/en not_active Abandoned
-
2005
- 2005-08-26 US US11/212,300 patent/US20050288349A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2268840C (en) | Benzimidazole-2-carbamates for the treatment of viral infections and cancer | |
US5900429A (en) | Method for inhibiting the growth of cancers | |
US6090796A (en) | Pharmaceutical composition for inhibiting the growth of cancers | |
CA2217952C (en) | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers | |
US5932604A (en) | Pharmaceutical compositions for the treatment of viral infections | |
EP0841914A2 (en) | Use of griseofulvin for inhibiting the growth of cancers | |
US20010053773A1 (en) | Method for inhibiting the growth of cancers | |
US20010041678A1 (en) | Compositions and methods for treating cancer | |
AU763272B2 (en) | Benzimidazole-2-carbamates for the treatment of viral infections and cancer | |
AU730920B2 (en) | A pharmaceutical composition containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers | |
MXPA99006961A (en) | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |